Please upgrade your browser.
Cancer Genetics Announces Compelling Diagnostic Sensitivity (99%) and Accuracy (93%) for Its Patent-Protected Genomic Kidney Cancer Test
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI") announced today the results of a collaborative study conducted with The Cleveland Clinic to validate CGI's kidney cancer microarray test.
Virginia Cancer Patient's Insurance Terminated Due To ObamaCare
Neurological status at surgery, the grade of the original nephrectomy specimen and activity of the systemic disease were factors found to influence a patient’s survival after spine surgery for metastatic spinal renal cell carcinoma...
CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that interferes with tumor metabolism and blocks cancer cell growth and survival.
Overall survival at 10 years was 94.0% with nephron-sparing surgery and 89.7% with radical nephrectomy, with a hazard ratio of 0.50.
Receipt of a blood transfusion significantly reduced cancer-specific (68 vs 92%) and recurrence-free survival (63 vs 88%) at 5-years’ follow-up on univariate analysis.
The Phase 1b/2 trial will evaluate Pexa-Vec in combination with metronomic cyclophosphamide, a drug used in combination with other therapies to treat a wide variety of cancers.
Yet, it is still a cancer that is hardly ever talked about.
Forty-nine-month survival in a metastatic renal cell carcinoma patient across six lines of targeted therapy
The survival and prognosis of mRCC patients may thus be significantly improved with the suitable use of newer targeted agents.
Cancer Genetics, Inc. (Nasdaq: CGIX) announced that new data that further validates its UroGenRA-Kidney diagnostic test for renal cell cancer...
|Powered by NeonCRM|